Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06286241

Acronym

Step down ward

Enrollment

344

Registered

2024-02-29

Start date

2024-03-25

Completion date

2024-07-30

Last updated

2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

multiple myeloma, autologous stem cell transplantation, HEPA-filtered room, non-HEPA-filtered room

Brief summary

The goal of this observational study is to comparison of the complications in multiple myeloma patients who received autologous stem cell transplantation between in HEPA-filtered room and non-HEPA-filtered room. The main questions it aims to answer are: * The incidence of febrile neutropenia, infection, and duration of hospital stay * 2-year progression free survival Participants will be collected the data of baseline diagnosis, treatment, treatment results and complications during admission and follow-up visits from hospital medical record.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* aged 18 - 65 years old * Patients with multiple myeloma undergoing treatment with autologous stem cell transplantation and having a Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score less than or equal to 2 * Patients must provide signed consent to participate in the research if they undergo ASCT after the study has been approved. * If patients undergo ASCT before the study approval, retrospective data will be collected.

Exclusion criteria

* Patients with concomitant other types of cancer * Patients who refuse to participate in the study.

Design outcomes

Primary

Measure	Time frame	Description
febrile neutropenia	during admission	incidence of febrile neutropenia
Infection	during admission	incidence of Infection
duration of admission	during admission	duration of admission
progression free survival	2 years	duration of survival

Contacts

Primary ContactChutima Kunacheewa, MD

chutima.kua@mahidol.ac.th+66896790959

Backup ContactWeerapat Owattanapanich, MD

weerapat.owa@mahidol.ac.th+66891081983

Outcome results